- Home
- TNMG vs MTVA Comparison
TNMG vs MTVA Comparison
Compare TNMG & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNMG
- MTVA
- Stock Information
- Founded
- TNMG 2023
- MTVA 2014
- Country
- TNMG Japan
- MTVA United States
- Employees
- TNMG N/A
- MTVA N/A
- Industry
- TNMG
- MTVA
- Sector
- TNMG
- MTVA
- Exchange
- TNMG NYSE
- MTVA NYSE
- Market Cap
- TNMG 14.1M
- MTVA 14.3M
- IPO Year
- TNMG N/A
- MTVA N/A
- Fundamental
- Price
- TNMG $0.46
- MTVA $0.68
- Analyst Decision
- TNMG
- MTVA Strong Buy
- Analyst Count
- TNMG 0
- MTVA 2
- Target Price
- TNMG N/A
- MTVA $7.50
- AVG Volume (30 Days)
- TNMG 134.1K
- MTVA 65.6K
- Earning Date
- TNMG 08-01-2025
- MTVA 08-13-2025
- Dividend Yield
- TNMG N/A
- MTVA N/A
- EPS Growth
- TNMG N/A
- MTVA N/A
- EPS
- TNMG N/A
- MTVA N/A
- Revenue
- TNMG $48,493,897.00
- MTVA N/A
- Revenue This Year
- TNMG N/A
- MTVA N/A
- Revenue Next Year
- TNMG N/A
- MTVA N/A
- P/E Ratio
- TNMG N/A
- MTVA N/A
- Revenue Growth
- TNMG 35.31
- MTVA N/A
- 52 Week Low
- TNMG $0.26
- MTVA $0.60
- 52 Week High
- TNMG $34.08
- MTVA $4.72
- Technical
- Relative Strength Index (RSI)
- TNMG N/A
- MTVA N/A
- Support Level
- TNMG N/A
- MTVA N/A
- Resistance Level
- TNMG N/A
- MTVA N/A
- Average True Range (ATR)
- TNMG 0.00
- MTVA 0.00
- MACD
- TNMG 0.00
- MTVA 0.00
- Stochastic Oscillator
- TNMG 0.00
- MTVA 0.00
About TNMG TNL MEDIAGENE
TNL Mediagene is principally engaged in digital advertising, integrated marketing, marketing survey, artificial intelligence technology, data analysis, content service platform and production of audio-visual programs. Geographically, the company generates the majority of its revenue from Taiwan.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.